Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC).
| Active ingredient / Technology | Brand name, examples | Indication range, EU as example1 |
| Capsaicin | QutenzaTM | Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain |
| Lidocaine | Versatis™* | Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) in adults |
| Zolmitriptan | Zomig™ AscoTop™ | FCT and ODT: In adults aged 18 years and older for acute treatment of migraine headache with or without aura Nasal Spray: In adults and adolescents aged 12 years and older for the acute treatment of migraine headache with or without aura and in adults for the treatment of cluster headache |
| Esomeprazole | Nexium™ | Tablets: Indicated in adolescents from the age of 12 years and in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) Indicated in adults for: In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers Patients requiring continued NSAID therapy - Healing of gastric ulcers associated with NSAID therapy. - Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk. Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers Treatment of Zollinger Ellison Syndrome In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori IV: Indicated in children and adolescents aged 1-18 years and in adults for: Gastric antisecretory treatment when the oral route is not possible, such as: · gastroesophageal reflux disease (GERD) in patients with esophagitis and/or severe symptoms of reflux Indicated in adults for: Gastric antisecretory treatment when the oral route is not possible, such as: · healing of gastric ulcers associated with NSAID therapy. · prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers Indicated in children and adolescents aged 1-18 years for: Gastric antisecretory treatment when the oral route is not possible, such as: · gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux Granules for oral suspension: Children 1-11 years old: Gastroesophageal Reflux Disease (GERD) - treatment of endoscopically proven erosive reflux esophagitis - symptomatic treatment of gastroesophageal reflux disease (GERD) Children over 4 years of age: In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori Adults and adolescents from the age of 12 years: Reference is made to the Nexium gastro-resistant tablet SmPC Nexium oral suspension may also be used by patients having difficulty swallowing dispersed Nexium gastro-resistant tablets |
| Fixed-dose combination of Esomeprazole and Naproxen | Vimovo™ | Symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient. |
| Proprietary hot melt extrusion (HME) technology platform | Intac™ | Technology to raise barriers to non-oral routes of abuse of active pharmaceutical ingredients (APIs) with abuse potential |
1 Status: March 2019.
